300149 睿智医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.575-17.089-48.47716.827-18.316
总资产报酬率 ROA (%)0.356-10.224-29.3729.037-9.647
投入资产回报率 ROIC (%)0.400-11.502-32.93910.070-10.735

边际利润分析
销售毛利率 (%)27.55321.80025.93525.42331.690
营业利润率 (%)1.705-22.350-82.25556.350-21.021
息税前利润/营业总收入 (%)2.440-23.476-81.32255.826-16.483
净利润/营业总收入 (%)0.877-23.347-80.54927.320-23.783

收益指标分析
经营活动净收益/利润总额(%)6.27226.5216.392-11.3152.377
价值变动净收益/利润总额(%)93.731-3.3650.098190.871-3.061
营业外收支净额/利润总额(%)5.5636.3920.362-2.5751.559

偿债能力分析
流动比率 (X)2.0961.8581.7041.7490.694
速动比率 (X)2.0691.8251.6391.6910.625
资产负债率 (%)35.77037.96739.98837.76252.839
带息债务/全部投入资本 (%)9.61710.54610.32915.54431.887
股东权益/带息债务 (%)736.559648.516643.036443.387162.182
股东权益/负债合计 (%)176.154160.194147.585163.12188.150
利息保障倍数 (X)3.846-58.773-66.00862.684-3.384

营运能力分析
应收账款周转天数 (天)61.93881.73895.71891.81476.617
存货周转天数 (天)4.7079.32915.09420.31019.267